// App-Quantinova.ai

2212 : Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials

Researchers

Presenter

  • Hermine Brunner

Principal Investigators

  • Athimalaipet Ramanan

  • Gerd Horneff

  • Kirsten Minden

  • Inmaculada Calvo Penades

  • Mauro Zucchetto

  • Laura Brockwell

  • Oliver Gordon

  • Fabrizio De Benedetti

Medical Centers

  • Division of Rheumatology, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH

  • Bristol Royal Hospital for Children, Bristol, United Kingdom

  • Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Molecular Biology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain

  • Parexel International, Milano, Italy

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy

Locations

  • United States

  • United Kingdom

  • Germany

  • Spain

  • Italy

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved